Bacterial Conjunctivitis Drugs Market is likely to reduce to US$439.8 mn by 2024
The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.
Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=11315
Rising Prevalence of MDROs Creates Serious Challenge for Market’s Growth
Apart from this, the rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market’s growth over the coming years.
Although the market is facing a number of restraints at present, it may experience a little relief in future if the product development partnerships (PDPs) models for business are implemented by participants. As various research and development procedures incur a high amount, exerting substantial pressure on pharma companies, strategic alliances with small biotech research organizations will prove to be beneficial for both the parties.u-s-bacterial-conjunctivitis-drugs-market
Request Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11315
Market Encroachment by Generic Variations to Limit Demand for Topical Fluoroquinolones
Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. The demand for topical fluoroquinolones is the highest among all classes of bacterial conjunctivitis drugs in the U.S. However, the segment is projected to be hindered severely in the coming years, owing to the forthcoming patent expirations of bestselling drugs of this class, such as Vigamox, Moxeza, and Zymaxid by the end of 2016.
The market’s opportunity will also be hurt significantly over the next few years due to the encroachment by generic variations of these drugs and decline from US$361.9 mn in 2013 to US$286.4 mn by 2024.
Buy Full Bacterial Conjunctivitis Drugs Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=11315
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bacterial Conjunctivitis Drugs Market is likely to reduce to US$439.8 mn by 2024 here
News-ID: 790687 • Views: 147
More Releases from Transparency Market Research
Vascular Closure Devices Market Demands, Industry Size, Supply, Sales and Manufa …
Compliance with New EU-MDR May Lead to Shortage of Medical Devices amidst COVID-19 Crisis The European Parliament recently announced the postponement of the implementation of the new Medical Device Regulation (MDR) by a year, due to the unprecedented COVID-19 (coronavirus) outbreak. This will help medtech companies in the vascular closure devices market to stabilize their operations, owing to the debilitating consequences of the pandemic. This postponement is to come in practice
Laparoscopy Devices Market Offering Trends, Share, Size, Growth Until the End of …
Risk of Aerosolization of Coronavirus May Hamper Market Growth The laparoscopy devices market is projected to experience a slowdown during the COVID-19 outbreak, as minimally invasive surgical procedures carry the risk of aerosolization of blood-borne viruses. The SAGE (Scientific Advisory Group for Emergencies) and the EAES (European Association for Endoscopic Surgeons) have recommended patients to postpone their surgeries if not urgent due to the ongoing coronavirus outbreak. SAGE and EAES have laid
Clinical Trials Market Growth Opportunities Investment Analysis Report 2020-2030
Success of Clinical Trials for COVID-19 Vaccines Boosts Market Growth The coronavirus pandemic has brought research labs and healthcare institutions under great scrutiny for accelerating the clinical trials for COVID-19 vaccines. As such, the success in these clinical trials has led to global recognition of India for supplying several lack of free doses to Brazil, Bangladesh, Algeria, and South Africa. Countries such as Sri Lanka are following suit whilst creating incremental
Prefilled Syringes Market Share And Industry Trends, Forecasts Till and Million …
Prefilled Syringes Market Outlook 2031 The global prefilled syringes market was valued at US$ 13.6 Bn in 2021 The global market is projected to advance at a CAGR of 10.1% from 2022 to 2031 The global prefilled syringes market is anticipated to reach more than US$ 35.7 Bn by the end of 2031 Report Overview: https://www.transparencymarketresearch.com/prefilled-syringes-market.html Global Prefilled Syringes Market Introduction Prefilled syringe is a disposable syringe that already contains the substance to be injected.